Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5500.0
(0.36%)
KRW 5500.0
(0.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1514.45 Billion KRW | 5.79% |
| 2022 | 1431.54 Billion KRW | 6.98% |
| 2021 | 1338.18 Billion KRW | 7.59% |
| 2020 | 1243.76 Billion KRW | 0.45% |
| 2019 | 1238.25 Billion KRW | 4.92% |
| 2018 | 1180.21 Billion KRW | 3.39% |
| 2017 | 1141.56 Billion KRW | 8.06% |
| 2016 | 1056.42 Billion KRW | 10.57% |
| 2015 | 955.45 Billion KRW | 82.94% |
| 2014 | 522.27 Billion KRW | 11.51% |
| 2013 | 468.38 Billion KRW | 40.81% |
| 2012 | 332.64 Billion KRW | 5.94% |
| 2011 | 313.98 Billion KRW | 8.48% |
| 2010 | 289.43 Billion KRW | 4.65% |
| 2009 | 276.58 Billion KRW | 0.15% |
| 2008 | 276.17 Billion KRW | 10.24% |
| 2007 | 250.52 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 412.81 Billion KRW | 0.08% |
| 2024 Q1 | 412.48 Billion KRW | 7.33% |
| 2023 FY | 1514.45 Billion KRW | 5.79% |
| 2023 Q4 | 384.3 Billion KRW | -3.4% |
| 2023 Q3 | 397.83 Billion KRW | 5.99% |
| 2023 Q2 | 375.35 Billion KRW | 5.16% |
| 2023 Q1 | 356.94 Billion KRW | -6.03% |
| 2022 Q1 | 312.24 Billion KRW | -13.45% |
| 2022 Q2 | 361.81 Billion KRW | 15.87% |
| 2022 FY | 1431.54 Billion KRW | 6.98% |
| 2022 Q3 | 377.64 Billion KRW | 4.38% |
| 2022 Q4 | 379.83 Billion KRW | 0.58% |
| 2021 Q3 | 350.43 Billion KRW | 5.29% |
| 2021 Q1 | 294.14 Billion KRW | -3.45% |
| 2021 Q2 | 332.83 Billion KRW | 13.16% |
| 2021 FY | 1338.18 Billion KRW | 7.59% |
| 2021 Q4 | 360.76 Billion KRW | 2.95% |
| 2020 Q2 | 322.58 Billion KRW | 7.29% |
| 2020 Q3 | 315.87 Billion KRW | -2.08% |
| 2020 Q1 | 300.67 Billion KRW | -5.23% |
| 2020 FY | 1243.76 Billion KRW | 0.45% |
| 2020 Q4 | 304.64 Billion KRW | -3.55% |
| 2019 Q1 | 293.96 Billion KRW | -0.24% |
| 2019 Q3 | 303.54 Billion KRW | -6.16% |
| 2019 FY | 1238.25 Billion KRW | 4.92% |
| 2019 Q4 | 317.26 Billion KRW | 4.52% |
| 2019 Q2 | 323.48 Billion KRW | 10.04% |
| 2018 Q2 | 298.03 Billion KRW | 8.28% |
| 2018 Q3 | 312.26 Billion KRW | 4.78% |
| 2018 Q4 | 294.67 Billion KRW | -5.63% |
| 2018 FY | 1180.21 Billion KRW | 3.39% |
| 2018 Q1 | 275.24 Billion KRW | -1.04% |
| 2017 Q1 | 264.27 Billion KRW | -0.37% |
| 2017 Q4 | 278.12 Billion KRW | -6.35% |
| 2017 Q3 | 296.99 Billion KRW | -1.71% |
| 2017 FY | 1141.56 Billion KRW | 8.06% |
| 2017 Q2 | 302.16 Billion KRW | 14.34% |
| 2016 Q2 | 278.33 Billion KRW | 13.89% |
| 2016 Q3 | 268.44 Billion KRW | -3.55% |
| 2016 Q4 | 265.25 Billion KRW | -1.19% |
| 2016 FY | 1056.42 Billion KRW | 10.57% |
| 2016 Q1 | 244.39 Billion KRW | -11.38% |
| 2015 Q4 | 275.77 Billion KRW | -0.87% |
| 2015 FY | 955.45 Billion KRW | 82.94% |
| 2015 Q3 | 278.17 Billion KRW | -0.39% |
| 2015 Q2 | 279.27 Billion KRW | 128.47% |
| 2015 Q1 | 122.23 Billion KRW | -5.01% |
| 2014 Q3 | 144.72 Billion KRW | 4.6% |
| 2014 Q2 | 138.35 Billion KRW | 25.2% |
| 2014 FY | 522.27 Billion KRW | 11.51% |
| 2014 Q1 | 110.51 Billion KRW | -4.18% |
| 2014 Q4 | 128.67 Billion KRW | -11.09% |
| 2013 Q3 | 132.91 Billion KRW | 9.66% |
| 2013 Q4 | 115.32 Billion KRW | -13.23% |
| 2013 FY | 468.38 Billion KRW | 40.81% |
| 2013 Q1 | 98.93 Billion KRW | 18.67% |
| 2013 Q2 | 121.21 Billion KRW | 22.52% |
| 2012 Q2 | 87.62 Billion KRW | 18.28% |
| 2012 Q3 | 87.36 Billion KRW | -0.3% |
| 2012 Q4 | 83.36 Billion KRW | -4.58% |
| 2012 FY | 332.64 Billion KRW | 5.94% |
| 2012 Q1 | 74.08 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 81.38 Billion KRW | 20.22% |
| 2011 Q3 | 84.14 Billion KRW | 3.4% |
| 2011 Q1 | 67.69 Billion KRW | -5.97% |
| 2011 FY | 313.98 Billion KRW | 8.48% |
| 2010 Q3 | 77.2 Billion KRW | 0.23% |
| 2010 Q2 | 77.02 Billion KRW | 21.87% |
| 2010 Q1 | 63.2 Billion KRW | -6.83% |
| 2010 Q4 | 71.99 Billion KRW | -6.75% |
| 2010 FY | 289.43 Billion KRW | 4.65% |
| 2009 FY | 276.58 Billion KRW | 0.15% |
| 2009 Q4 | 67.84 Billion KRW | -8.5% |
| 2009 Q3 | 74.14 Billion KRW | 2.81% |
| 2009 Q1 | 62.49 Billion KRW | -8.03% |
| 2009 Q2 | 72.11 Billion KRW | 15.4% |
| 2008 Q3 | 77.42 Billion KRW | 9.36% |
| 2008 Q2 | 70.8 Billion KRW | 18.01% |
| 2008 FY | 276.17 Billion KRW | 10.24% |
| 2008 Q4 | 67.94 Billion KRW | -12.25% |
| 2008 Q1 | 59.99 Billion KRW | -7.73% |
| 2007 Q4 | 65.02 Billion KRW | -6.66% |
| 2007 Q2 | 66.32 Billion KRW | 33.99% |
| 2007 Q1 | 49.5 Billion KRW | 0.0% |
| 2007 FY | 250.52 Billion KRW | 0.0% |
| 2007 Q3 | 69.66 Billion KRW | 5.04% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -319.39% |
| Yuhan Corporation | 1858.98 Billion KRW | 18.533% |
| Yuhan Corporation | 1858.98 Billion KRW | 18.533% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1003.752% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1003.752% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1003.752% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -137.209% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -671.32% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | -33.785% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -102.325% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -102.325% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -102.325% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -2814.932% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | -72.14% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -1609.44% |
| HANDOK Inc. | 522.74 Billion KRW | -189.714% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -90.566% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -1018.729% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -1102.633% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -1633.506% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -1840.284% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -187.399% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -544.716% |
| Boryung Corporation | 859.62 Billion KRW | -76.176% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -737.814% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -418.42% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -308.718% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -308.718% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -154.715% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -1022.568% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -557.333% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -793.128% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -656.363% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -656.363% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -442.925% |
| CKD Bio Corp. | 160.35 Billion KRW | -844.451% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | -10.116% |
| JW Holdings Corporation | 928.07 Billion KRW | -63.183% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -902.477% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | -1.581% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -128.087% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 9.282% |
| JW Lifescience Corporation | 206.86 Billion KRW | -632.114% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -152.091% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -108.489% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -574.72% |